Hutchison China Meditech share price today
(NASDAQ: HCM)

Name: Hutchison China Meditech Share Price Today (NASDAQ: HCM) - Hutchison China Meditech Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Hutchison China Meditech share price is $13.6 & ₹1,176.26 as on 24 Jan 2025, 2.30 'hrs' IST

$13.6

▲

-0.58

(-4.09%)

Market is closed - opens 8 PM, 24 Jan 2025

View live Hutchison China Meditech share price in Dollar and Rupees. Guide to invest in Hutchison China Meditech stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Hutchison China Meditech, along with analyst recommendations, forecasts, and comprehensive financials.

Hutchison China Meditech share price movements

Today's Low: $13.26
Today's High: $13.70
$13.60
2.5%
Downside
Day's Volatility :3.21%
Upside
0.73%
52 Weeks Low: $11.93
52 Weeks High: $21.92
$13.60
12.25%
Downside
52 Weeks Volatility :45.56%
Upside
37.96%

Hutchison China Meditech Returns

Period	Hutchison China Meditech Limited	Sector (Health Care)	Index (Russel 2000)
3 Months	-31.99%	-5.5%	0.0%
6 Months	-23.6%	-4.3%	0.0%
1 Year	2.38%	1.6%	0.0%
3 Years	-49.28%	9.8%	-11.0%

Hutchison China Meditech Key Statistics

in dollars & INR

Previous Close	$14.18
Open	$13.7
Today's High	$13.7
Today's Low	$13.26
Market Capitalization	$2.4B
Today's Volume	$110.6K
52 Week High	$21.92
52 Week Low	$11.9343
Revenue TTM	$610.8M
EBITDA	$-110.2M
Earnings Per Share (EPS)	$-0.25
Profit Margin	-6.87%
Quarterly Earnings Growth YOY	-0.84%
Return On Equity TTM	-5.44%

How to invest in Hutchison China Meditech Stock (HCM) from India?

It is very easy for Indian residents to invest directly in Hutchison China Meditech from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Hutchison China Meditech stock in both Indian Rupees (INR) and US Dollars (USD). Search for Hutchison China Meditech or HCM on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Hutchison China Meditech or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Hutchison China Meditech shares which would translate to 0.064 fractional shares of Hutchison China Meditech as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Hutchison China Meditech, in just a few clicks!

Returns in Hutchison China Meditech for Indian investors in Rupees

Investment Value

₹1,00,000

Hutchison China Meditech investment value today

Current value as on today

₹1,02,249

Returns

₹2,249

(+2.25%)

Returns from Hutchison China Meditech Stock

₹1,805 (-1.81%)

Dollar Returns

₹4,054 (+4.05%)

Indian investors sentiment towards Hutchison China Meditech

9.62%

Period: Oct 25, 2024 to Jan 23, 2025. Change in 30 Days versus previous period

Investment in Hutchison China Meditech from India has grown in the last 30 days as on Jan 24, 2025. 9.62% more purchase transactions for Hutchison China Meditech in the last 30 days versus the previous period.

-18%

Period: Oct 25, 2024 to Jan 23, 2025. Change in 30 Days versus previous period

Search volume for Hutchison China Meditech on INDmoney from India has reduced in the last 30 days as on Jan 24, 2025. -18% less investors are searching Hutchison China Meditech in the last 30 days versus the previous period.

Global Institutional Holdings in Hutchison China Meditech

Analyst Recommendation on Hutchison China Meditech

Buy

90%Buy

9%Hold

0%Sell

Based on 22 Wall street analysts offering stock ratings for Hutchison China Meditech(by analysts ranked 0 to 5 stars)

Based on 22 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Hutchison China Meditech

What analysts predicted

Upside of 97.17%

Target:

$26.81

Current:

$13.60

Insights on Hutchison China Meditech

Price Movement
In the last 3 months, HCM stock has moved down by -33.6%
Increasing Revenue
Revenue is up for the last 3 quarters, 152.56M → 152.84M (in $), with an average increase of 0.1% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -33.88M → 12.90M (in $), with an average increase of 181.3% per quarter
HCM vs ITCI (1 yr)
In the last 1 year, Intra-cellular Therapies, Inc. has given 91.3% return, outperforming this stock by 89.1%
HCM vs ITCI (3 yr)
In the last 3 years, Intra-cellular Therapies, Inc. has given 198.1% return, outperforming this stock by 249.1%
Price to Sales
ForHCM every $1 of sales, investors are willing to pay $4.0, whereas for Intra-cellular Therapies, Inc., the investors are paying $20.9 for every $1 of sales.

Hutchison China Meditech Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$214.1M	↓ 11.23%
Net Income	$-74.8M	↑ 179.78%
Net Profit Margin	-34.94%	↓ 23.86%

	FY19	Y/Y Change
Revenue	$204.9M	↓ 4.31%
Net Income	$-144.4M	↑ 93.01%
Net Profit Margin	-70.47%	↓ 35.53%

	FY20	Y/Y Change
Revenue	$228.0M	↑ 11.27%
Net Income	$-194.6M	↑ 34.76%
Net Profit Margin	-85.34%	↓ 14.87%

	FY21	Y/Y Change
Revenue	$356.1M	↑ 56.21%
Net Income	$-227.7M	↑ 17.01%
Net Profit Margin	-63.93%	↑ 21.41%

	FY22	Y/Y Change
Revenue	$426.4M	↑ 19.73%
Net Income	$-410.1M	↑ 80.16%
Net Profit Margin	-96.18%	↓ 32.25%

	FY23	Y/Y Change
Revenue	$838.0M	↑ 96.52%
Net Income	$100.8M	↓ 124.57%
Net Profit Margin	12.03%	↑ 108.21%

	Q4 FY22	Q/Q Change
Revenue	$112.2M	↑ 0.0%
Net Income	$-99.0M	↑ 0.0%
Net Profit Margin	-88.24%	↑ 0.0%

	Q1 FY23	Q/Q Change
Revenue	$266.4M	↑ 137.51%
Net Income	$84.3M	↓ 185.14%
Net Profit Margin	31.63%	↑ 119.87%

	Q2 FY23	Q/Q Change
Revenue	$532.9M	↑ 100.0%
Net Income	$168.6M	↑ 100.0%
Net Profit Margin	31.63%	↑ 0.0%

	Q3 FY23	Q/Q Change
Revenue	$152.6M	↓ 71.37%
Net Income	$-33.9M	↓ 120.1%
Net Profit Margin	-22.21%	↓ 53.84%

	Q4 FY23	Q/Q Change
Revenue	$152.8M	↑ 0.18%
Net Income	$12.9M	↓ 138.07%
Net Profit Margin	8.44%	↑ 30.65%

	Q2 FY24	Q/Q Change
Revenue	$152.8M	↑ 0.0%
Net Income	$12.9M	↑ 0.0%
Net Profit Margin	8.44%	↑ 0.0%

	FY18	Y/Y Change
Profit	$70.2M	↑ 7.31%

	FY19	Y/Y Change
Profit	$44.7M	↓ 36.24%

	FY20	Y/Y Change
Profit	$39.5M	↓ 11.8%

	FY21	Y/Y Change
Profit	$97.9M	↑ 148.1%

	FY22	Y/Y Change
Profit	$115.3M	↑ 17.79%

	FY23	Y/Y Change
Profit	$453.6M	↑ 293.35%

	Q4 FY22	Q/Q Change
Profit	$-77.3M	↑ 0.0%

	Q1 FY23	Q/Q Change
Profit	$90.0M	↓ 216.39%

	Q2 FY23	Q/Q Change
Profit	$324.6M	↑ 260.78%

	Q3 FY23	Q/Q Change
Profit	$-14.2M	↓ 104.37%

	Q4 FY23	Q/Q Change
Profit	$62.8M	↓ 542.59%

	Q2 FY24	Q/Q Change
Profit	$62.8M	↑ 0.0%

	FY18	Y/Y Change
Operating Cash Flow	$-32.8M	↑ 267.29%
Investing Cash Flow	$43.8M	↓ 116.78%
Financing Cash Flow	$-8.2M	↓ 103.01%

	FY19	Y/Y Change
Operating Cash Flow	$-80.9M	↑ 146.33%
Investing Cash Flow	$119.0M	↑ 172.05%
Financing Cash Flow	$-1.5M	↓ 81.86%

	FY20	Y/Y Change
Operating Cash Flow	$-62.1M	↓ 23.29%
Investing Cash Flow	$-125.4M	↓ 205.39%
Financing Cash Flow	$296.4M	↓ 19954.92%

	FY21	Y/Y Change
Operating Cash Flow	$-204.2M	↑ 229.04%
Investing Cash Flow	$-306.3M	↑ 144.19%
Financing Cash Flow	$650.0M	↑ 119.28%

	FY22	Y/Y Change
Operating Cash Flow	$-268.6M	↑ 31.52%
Investing Cash Flow	$296.6M	↓ 196.82%
Financing Cash Flow	$-82.8M	↓ 112.73%

	Q4 FY22	Q/Q Change
Operating Cash Flow	$167.6M	↓ 287.52%
Investing Cash Flow	$18.4M	↑ 0.0%
Financing Cash Flow	$-766.6M	↑ 18770.68%

Hutchison China Meditech Technicals Summary

Sell

Neutral

Buy

Hutchison China Meditech is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Hutchison China Meditech Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Hutchison China Meditech Limited	-2.0%	-23.6%	2.38%	-49.28%	-38.4%
Intra-cellular Therapies, Inc.	49.17%	58.17%	89.83%	172.62%	447.12%
Haleon Plc Spon Ads	-5.34%	-0.11%	14.11%	24.43%	24.43%
Zoetis Inc.	0.67%	-7.35%	-11.05%	-14.66%	22.56%
Neurocrine Biosciences Inc.	5.56%	-0.03%	4.08%	93.28%	48.77%
Viatris Inc.	-11.31%	-7.78%	-5.11%	-24.11%	-31.82%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Hutchison China Meditech Limited	30.0	NA	0.0	-0.22	-0.05	-0.06	NA	0.87
Intra-cellular Therapies, Inc.	NA	NA	0.0	-0.7	-0.1	-0.07	NA	10.8
Haleon Plc Spon Ads	28.0	28.0	1.65	0.36	0.07	0.04	0.02	1.82
Zoetis Inc.	31.32	31.32	2.61	5.88	0.47	0.15	0.01	11.59
Neurocrine Biosciences Inc.	39.03	39.03	0.34	6.6	0.16	0.12	NA	26.87
Viatris Inc.	224.4	NA	0.07	2.69	-0.04	0.02	0.04	16.58

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Hutchison China Meditech Limited	Buy	$2.4B	-38.4%	30.0	-6.87%
Intra-cellular Therapies, Inc.	Buy	$13.4B	447.12%	NA	-14.07%
Haleon Plc Spon Ads	Buy	$41.8B	24.43%	28.0	10.75%
Zoetis Inc.	Buy	$75.2B	22.56%	31.32	26.55%
Neurocrine Biosciences Inc.	Buy	$14.9B	48.77%	39.03	17.21%
Viatris Inc.	Hold	$13.5B	-31.82%	224.4	-5.87%

About Hutchison China Meditech

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.

Organization	Hutchison China Meditech
Employees	1970
CEO	Dr. Wei-Guo Su B.Sc., Ph.D.
Industry	Health Technology

Management People of Hutchison China Meditech

Name	Title
Dr. Wei-Guo Su B.Sc., Ph.D.	CEO, Chief Scientific Officer & Executive Director
Mr. Chig Fung Cheng BEc, CA	CFO & Executive Director
Ms. Edith Shih BSE, C.S., CGP, EdM, FCIS, FCS, FCS(PE), M.A., P.E	Company Secretary & Non-Executive Director
Ms. Yiling Cui	Executive VP & Head of Operations
David Ng	Head of Investor Relations & Capital Strategies
Mr. Charles George Rupert Nixon	Group General Counsel
Mr. Kin Hung Lee M.B.A.	Senior Vice President of Corporate Management & Communications
Ms. Selina Zhang	Senior Vice President of Global Human Resources
Dr. Qingmei Wang Ph.D.	Senior Vice President of Business Development & Strategic Alliances
Dr. Zhenping Wu M.B.A, Ph.D.	Executive Vice President of Pharmaceutical Science & Manufacturing

Important FAQs about investing in Hutchison China Meditech (HCM) from India :

What is Hutchison China Meditech share price today?

Hutchison China Meditech share price today stands at $13.60, Open: $13.70 ; Previous Close: $14.18 ; High: $13.70 ; Low: $13.26 ; 52 Week High: $21.92 ; 52 Week Low: $11.93. The stock opens at $13.70, after a previous close of $14.18. The stock reached a daily high of $13.70 and a low of $13.26, with a 52-week high of $21.92 and a 52-week low of $11.93.

Can Indians buy Hutchison China Meditech shares?

Yes, Indians can invest in the Hutchison China Meditech (HCM) from India.

With INDmoney, you can buy Hutchison China Meditech at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Hutchison China Meditech at zero transaction cost.

How can I buy Hutchison China Meditech shares from India?

It is very easy to buy Hutchison China Meditech from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Hutchison China Meditech be purchased?

Yes, you can buy fractional shares of Hutchison China Meditech with INDmoney app.

What are the documents required to start investing in Hutchison China Meditech stocks?

To start investing in Hutchison China Meditech, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.